Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Non Operating Income (2020 - 2025)

Maxcyte (MXCT) has disclosed Non Operating Income for 6 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income fell 30.57% to $1.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.9 million, a 25.48% decrease, with the full-year FY2024 number at $10.1 million, down 2.26% from a year prior.
  • Non Operating Income was $1.7 million for Q3 2025 at Maxcyte, down from $1.9 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.8 million in Q4 2023 to a low of -$732500.0 in Q1 2021.
  • A 5-year average of $1.5 million and a median of $1.9 million in 2022 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: soared 10506.52% in 2022, then plummeted 30.57% in 2025.
  • Maxcyte's Non Operating Income stood at $81000.0 in 2021, then skyrocketed by 2296.42% to $1.9 million in 2022, then soared by 45.18% to $2.8 million in 2023, then fell by 18.24% to $2.3 million in 2024, then dropped by 24.78% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Non Operating Income are $1.7 million (Q3 2025), $1.9 million (Q2 2025), and $2.0 million (Q1 2025).